Effects of XXXX and @entity2049 on the EEG and cognition in healthy volunteers.

@entity1 @entity2682 @entity2050 @entity73 @entity2049 @entity2359
PURPOSE: Antiepileptic drug (AED) therapy can be associated with @entity2359 side effects including @entity73 . Objective methods for detection of @entity2359 in individual @entity1 would be useful. We studied the effects of @entity2682 (GBP) and @entity2049 ( @entity2050 ) on neurophysiologic and cognitive/behavioral measures in healthy volunteers. METHODS: In a 12-week, randomized, double-blind, parallel-group study of @entity2050 and GBP in healthy volunteers, 23 subjects completed the protocol. All achieved the target dose of 1,200 mg @entity2050 or 3,600 mg GBP. A structured EEG for quantitative analysis and a cognitive test battery were administered before AED therapy and again after 12 weeks of therapy. Test-retest differences were compared with those of 72 untreated control subjects. RESULTS: Both @entity2050 and GBP significantly decreased the peak frequency of the posterior (alpha) rhythm, with @entity2050 exerting a greater effect. Ten @entity2050 and six GBP subjects exceeded the 95% confidence interval (CI) for an individual. Cognitive tests revealed AED vs. control group effects for two of seven measures (Digit Symbol, Stroop) and all subjective measures. However, few subjects exceeded the 95% CI for any objective test. Differences between @entity2050 and GBP were not significant. Greater EEG slowing was associated with greater subjective @entity2359 and poorer test-retest performance on a cognitive test summary measure. CONCLUSIONS: Prolonged @entity2050 and GBP therapy induced EEG slowing that correlated with @entity73 and often exceeded the confidence interval for individual subjects. Quantitative EEG measures may be useful in the objective determination of AED-related @entity2359 .
